

**2023** KOREA INTERCHANGE SEOUL | 11-14 DECEMBER



#### State of the CDISC Standards

Peter Van Reusel, Chief Standards Officer, CDISC



### **Meet the Speaker**

Peter Van Reusel

Title: Chief Standards Officer Organization: CDISC

Peter Van Reusel provides executive leadership to the development and implementation of clinical standards in line with CDISC's strategy and operational plans, working closely with the President and CEO, as well as CDISC staff and stakeholders. He has over 20 years' experience in senior roles in pharma and at CROs, providing standards expertise and carrying out other standards work in various organizational settings. A long-time, CDISC-authorized instructor, Peter has helped significantly in developing CDISC training courses.

He previously served as CDISC's European Liaison, shepherding relationships with key European regulatory, academic, and biopharma stakeholders. Peter is also an active PHUSE collaborator.

### Agenda

1. CDISC 360: End to End Standards

2. Key Initiatives for 2023 and Beyond

### **CDISC 360: End to End Standards**



### 

#### BRIDG, CONTROLLED TERMINOLOGY AND GLOSSARY



### **Our Start**



### **Continued Evolution of Standards**

- Standardizing the meaning of the information
- Defining the data processing (data flow)
- Providing machine-executable data flow definitions
- Standardizing missing parts:
  - Protocol content
  - Collection instruments
  - · Analysis / endpoint definitions and outputs
- Publishing standards from one trusted source
- Making standards less complex for the end users







. . . . . . .

### Key Initiatives for 2023 and Beyond





### **Digital Data Flow (DDF)**

#### Write Once, Read Many

**TODAY:** Document-based paradigm for protocol creation, interpretation, and transcription into consuming systems

**TOMORROW:** Digital paradigm for protocol creation, with fully automated data flow and interoperability between systems





### **ICH M11 Guideline**

#### Structure and Content of a Clinical Protocol

The **Template** presents the format and structure of the protocol, including the table of contents, common headers, and contents



NICAL ELECTRONIC STRUCTURED HARMONISE PROTOCOL (CESHARP)

M11 TEMPLATE

The **Technical Specification** presents the conformance, cardinality, and other technical attributes that enable the interoperable electronic exchange of protocol content





### **ICH M11 Clinical Protocol Template**

#### 4.1 Description of Trial Design

Describe the trial intervention model (for example, single group, parallel group, cross-over, factorial, sequential), the expected number of participants, and the control method (for example, placebo, active comparator, low dose, historical, standard of care, sham procedure, or none [uncontrolled]).

If applicable, indicate the type of trial (for example, superiority, non-inferiority, dose escalation, or equivalence).

#### **Opportunities for Standardization**

• Integration of structured content into narrative content



### **ICH M11 Technical Specification**

#### **Trial Design**

Term (Variable)	Type of Trial
Data Type	List
Topic, Value or	D
Header	
Definition	
User Guidance	
Conformance	Required
Cardinality	
Relationship content	Trial Design
from ToC	
representing the	
protocol hierarchy	
Relationship	
(reference to high	
model)	
Value	Superiority, non-inferiority, dose escalation, or equivalence
Business rules	Value Allowed: Yes
	Relationship: n/a
	Concept: n/a
Duplicate field in	
other sections	

## **Opportunities for Standardization**

- Variables
- Concept/terminology
- Codelist
- Conformance



#### **CDISC and Vulcan engagement**



\* M11 Clinical Electronic Structure Harmonized Protocol presentation - Panagiotis Telonos, EMA - CDISC Europe Interchange 2023



### **Biomedical Concepts**

A pragmatic, iterative approach to creating biomedical concepts with a focus on providing tangible value for the CDISC community

### Key Objectives:

- Reduce variability in standards implementations
- Increase metadata-driven automation
- Reduce barriers to operational implementation

#### **Key Components:**

- Conceptual layer
- Implementation layer
- Logical data model

COISC





15



### **Biomedical Concepts: Semantics**

Representation of a BC in a specific standard with implementation details such as value level metadata, formats, terminology – alignment across standards





### **Analysis Results Standards (ARS)**



• Dataset structure and metadata for results to support traceability, use, and automation



### **ARS Key Results**



Logical model that describes analysis results and associated metadata



User Guide to illustrate how analysis results metadata can be used to create a structure to represent analysis results as data



User Guide to illustrate how analysis results metadata can be used prospectively to drive automation





### **ARS Release Plan**

#### Analysis Results Standard Model v1.0

• The logical model to support a technical specification and an analysis results dataset

#### Analysis Results User Guide Version 1.0

- How analysis results metadata can be used to create a structure to represent analysis results as data
- How analysis results metadata can be used prospectively to drive automation
- Includes common safety examples

#### Today

- Public Review in October 2023
- Final Release: Dec 2023/Jan 2024

#### Future

- Example implementation package with four TFL examples!
- Ideation of eTFL Portal



### **Digital Health Technologies (DHT)**

Increased industry focus on digital health technologies



## FDA | CDER | Small Business and Industry Assistance

#### FDA to Host Digital Health Technologies for Drugs Public Workshop

The U.S. Food and Drug Administration is hosting the virtual public workshop "Understanding Priorities for the Development of Digital Health Technologies to Support Clinical Trials for Drug Development and Review" on March 28th and 29th, 2023. The workshop will focus on understanding the priorities and challenges of developing Digital Health Technologies (DHTs) to support clinical drug trials.

The workshop will be convened by the Robert J. Margolis, MD, Center for Health Policy at Duke University under a cooperative agreement with FDA.

For more information on the Digital Health Technologies virtual public workshop and to register, please visit FDA's Meeting's, Conferences & Workshops (Drugs).

### **Standards Through Partnership**



To advance the ethical, effective, equitable, and safe use of digital medicine to redefine healthcare and improve lives

#### 

Digital Health Measurement Collaborative Community

#### 

A collaborative community hosted by DiMe with the FDA's Center for Devices and Radiological Health cdisc

To advance data standards and transform incompatible formats, inconsistent methodologies, and diverse perspectives to amplify data's impact for research and global health.

#### Volunteers





### **CDISC Digital Health Technologies (DHT)**

#### Partner

- Expert organizations
- Expert volunteers

#### Standardize

Concepts, device attributes, endpoints, and best practices



#### Resources





Scope June - October

cdisc



**Develop** Start in November

Deliver

#### Robust & aligned

2024 staged releases

### CDISC Open Rules Engine (CORE) Learn more: https://www.cdisc.org/core







\* CDISC Open-Source Alliance

#### **CORE** Rules Governance





### **First Vendor Launch**

### Introducing Formedix CORE: a freeto-use desktop app incorporating the CDISC Open Rules Engine

Formedix CORE is a free, downloadable Windows desktop application that allows you to validate datasets using the CDISC Open Rules Engine (CORE). The application provides an easy way to run validations on local data and identify standards conformance issues.



DOWNLOAD CORE



### **Next Milestone**

#### Complete Ruleset for:

- SDTMIG 3.2 and SDTMIG 3.3
- Define.xml crosscheck rules
- FDA validator rules v1.6 (that apply to SDTMIG 3.2 and SDTMIG 3.3)
- FDA technical rejection criteria

#### **CORE Engine Stable Release**

- Engine can run all the rulesets above
- Thorough testing and validation documentation



Implementers can integrate this stable version Drive adoption and test with real study data

#### Purpose

· Test with real study data and establish the rules governance process



# SAS v5 XPT format is the current standard for exchanging tabular datasets

Currently Mandated by regulatory agencies

#### • Limitations of XPT v5

- Numeric limitations, antiquated format
- Stores data in its own numeric way
- Character limitations, no UTF-8 encoding
  - No support for characters from other languages
- String & Column limitations (variable names > 8, labels > 40, data > 200)
- No metadata extensibility
- Considered outdated and antiquated
- Technology 'stigma'



### **Dataset-JSON Pilot**



#### Milestone 1: Short Term

- Pilot submissions using JSON format with existing XPT ingress/egress to carry the same data
- Same content, different suitcase, no disruption to business process on either side
- In parallel, evaluate how FDA toolset can support JSON format and identify tool upgrade roadmap
- Success Criteria: Accept Dataset-JSON as a transport format option (in addition to existing XPT format)

#### Milestone 2: Long Term

- Enhance the CDISC SDTM and ADaM standards beyond XPT limitations (e.g. Variable names > 8, labels > 40, data > 200
- New Define-XML/ Define-JSON based on ODM v2.0
- Enhanced conformance rules
- Collaborate with FDA to develop plan to retool their environment to natively consume JSON

Success Criteria: accept advanced Dataset-JSON as the only transport format option and deprecate XPT



### **Dataset-JSON Pilot**





### **CDISC Library: Standards as a Service**

Software Applications Consume Standards Metadata via the API



#### REST architecture principles at work

### **CDISC Open-Source Alliance (COSA)**

#### **Community Driven Development**

Supports and promotes open-source software projects that create tools for implementing or developing CDISC standards to drive innovation in the CDISC community





### **Relentless Collaboration**







### Thank you!

